TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
Summary
The Company intends to use the net proceeds from this offering for product development activities, including one or more clinical trials with TTX-MC138, its lead therapeutic candidate, and related investigational new drug (IND) enabling studies, and for working capital and other general corporate purposes. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The companys lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.This press release contains forward-looking statements that are subject to substantial risks and uncertainties, including statements related to the completion of the offering. Forward-looking statements are based on the Companys current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.